The Burden of COPD with Type 2 Inflammation in North-West Continental Europe
Authors:
- Hanna SandelowskyHSHanna Sandelowsky
- Anders LøkkeALAnders Løkke
- Janwillem KocksJKJanwillem Kocks
- Helle GrøttumHGHelle Grøttum
- Per BakkePBPer Bakke
- Tuula VasankariTVTuula Vasankari
Open Access
- 1 August 2025
- journal article
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 20, 2767-2785
Abstract
Chronic obstructive pulmonary disease (COPD) is a complex and heterogeneous disease that places a huge burden on patients, health systems and societies. Yet despite this, COPD is often neglected: it is frequently underdiagnosed or misdiagnosed, and since tobacco exposure is a primary risk factor for its development, patients are often stigmatized and marginalized because they are perceived as having a “self-inflicted” disease. COPD is primarily understood to be a functional disorder with chronic airway obstruction, yet there are several underlying inflammatory pathways. For most patients with COPD, type 1 (neutrophilic) inflammation is the main such pathway; however, a considerable proportion has type 2 inflammation (associated with elevated eosinophil numbers). COPD with type 2 inflammation may represent a distinct COPD phenotype and a “treatable trait”. In fact, the response to inhaled corticosteroids (ICS) is linked to blood eosinophil levels: treatment effects begin to increase in patients with blood eosinophil counts ≥100 cells/μL, and most treatment guidelines recommend considering ICS for patients with blood eosinophil counts ≥300 cells/μL. Data on the burden of COPD with type 2 inflammation are limited. COPD with type 2 inflammation may associate with poor outcomes, and higher blood eosinophil counts positively associate with an increased risk of moderate or severe exacerbations. Exacerbations are among the most dangerous aspects of COPD, accelerating disease progression and increasing morbidity and mortality. This review explores the burden of COPD – specifically eosinophilic COPD – across north-western Europe. It aims to provide information relevant to patients, clinicians and policymakers, educating them about type 2 inflammation and its contribution to the disease burden. It has been informed by multiple stakeholders, including patients, and offers practical and achievable recommendations for enhancing the care of all patients with COPD through a better understanding of COPD with type 2 inflammation.Keywords
This publication has 115 references indexed in Scilit:
- The prevalence of chronic obstructive pulmonary disease in Uppsala, Sweden – the Burden of Obstructive Lung Disease (BOLD) study: cross‐sectional population‐based studyThe Clinical Respiratory Journal, 2011
- Excessive costs of COPD in ever-smokers. A longitudinal community studyRespiratory Medicine, 2011
- Experiences of self‐blame and stigmatisation for self‐infliction among individuals living with COPDScandinavian Journal of Caring Sciences, 2011
- The Experience of Stigma in Chronic Obstructive Pulmonary DiseaseWestern Journal of Nursing Research, 2010
- ‘Feelings of Guilt due to Self-inflicted Disease’Journal of Health Psychology, 2010
- Prevalence and predictors of undiagnosed chronic obstructive pulmonary disease in a Norwegian adult general populationThe Clinical Respiratory Journal, 2009
- Stability and Reliability of Plasma Level of Lipid Biomarkers and Their Correlation with Dietary Fat IntakeDisease Markers, 2008
- Understanding the Social Consequences of Chronic Obstructive Pulmonary Disease: The Effects of Stigma and GenderProceedings of the American Thoracic Society, 2007
- COPD exacerbations: defining their cause and preventionThe Lancet, 2007
- Interobserver and intraobserver reproducibility of peripheral blood and oxygen pressure measurements in the assessment of lower extremity arterial diseaseJournal of Vascular Surgery, 2001